研究园简易版
·
经典书籍
·
期刊文章
·
有原文
·
完整版(可多选筛选、搜索)
·
首页
搜索
2026 年 · Clinical Trials(临床试验)
182 篇,新的在前。点标题看作者和摘要。
回到 2026 年
Selection Bias in Hybrid Randomized Controlled Trials Using External Controls: A Simulation Study
· SiM · 2026-11-13 · 在第 1 页
Sample size estimation for pre- and post-intervention design with incomplete observations of count outcomes
· SMMR · 2026-11-12 · 在第 1 页
Orthogonal Factorial Designs for Trials of Therapist‐Delivered Interventions: Randomizing Intervention‐Therapist Combinations to Patients
· SiM · 2026-11-10 · 在第 1 页
Dynamic borrowing via covariate-adjusted self-adapting mixture priors in clinical trials
· SMMR · 2026-11-04 · 在第 1 页
Sample Size and Power Calculation for Continuous Outcomes in Open-Cohort Stepped Wedge Designs With Multiple Interventions
· SiM · 2026-11-03 · 在第 2 页
Sample size determination for randomized decentralized clinical trials with longitudinal outcomes
· Biometrics · 2026-10-31 · 在第 2 页
Can discrete-time analyses be trusted for stepped wedge trials with continuous recruitment?
· SMMR · 2026-10-28 · 在第 2 页
Calibrated Bayes Analysis of Cluster-Randomized Trials
· SiM · 2026-10-26 · 在第 2 页
Which Small-Sample Correction Should be Used When Analyzing Stepped-Wedge Designs With Time-Varying Treatment Effects?
· SiM · 2026-10-22 · 在第 2 页
Bayesian Methods Incorporating Baseline Covariates for Borrowing Historical Control Data in Randomized Clinical Trials: A Neutral Comparison Study
· SiM · 2026-10-22 · 在第 2 页
Addressing Missing Data in Clinical Trials With a Hybrid Control Arm
· SiM · 2026-10-22 · 在第 2 页
Estimating Marginal Odds Ratios for Cluster Randomized Trials: The Cluster-Level GLM
· SiM · 2026-10-21 · 在第 2 页
Clinically Interpretable Time-To-Event Testing in Randomized Clinical Trials: Milestone Survival Combined With Restricted Mean Survival Time
· SiM · 2026-10-16 · 在第 3 页
Treatment comparisons using a measurement during follow-up and a right-censored time-to-event outcome
· SMMR · 2026-10-15 · 在第 3 页
Cluster-level analysis in three-level cluster randomised trials with multi-level covariate-dependent missingness
· SMMR · 2026-10-15 · 在第 3 页
Valid Data-Driven Subgroup Selection With Uniform Guarantees in Clinical Trials
· SiM · 2026-10-13 · 在第 3 页
Using Joint Models in Phase I Dose-Finding Designs in Oncology: Considerations for Frequentist Approaches
· SiM · 2026-10-13 · 在第 3 页
A Multi-Task Learning Approach for Identifying Prognostic Variables Across Multiple Historical Clinical Trials
· SiM · 2026-10-13 · 在第 3 页
Group Sequential Sample Size for Comparing Two Survival Probabilities at a Specific Time Point
· SiM · 2026-10-09 · 在第 4 页
Statistical Inference with Mixed-Effect Model for Covariate-Adaptive Randomized Experiments
· JASA · 2026-10-06 · 在第 4 页
A Bayesian Adaptive Design for Assessing Treatment Effect Consistency in Bridging Studies
· SiM · 2026-09-30 · 在第 5 页
Response-adaptive randomization in clinical trials
· SMMR · 2026-09-29 · 在第 5 页
Generalizing Conditional Average Treatment Effects From Nested Randomized Trials to Trial-Eligible Individuals
· SiM · 2026-09-28 · 在第 5 页
A Bayesian adaptive digital twin design for avatar-driven cancer clinical trials
· Biometrics · 2026-09-26 · 在第 5 页
Evaluating Informative Cluster Size in Cluster Randomized Trials
· SiM · 2026-09-23 · 在第 6 页
An optimal two-step estimation approach for two-phase studies
· Biometrika · 2026-09-23 · 在第 6 页
Beyond Fixed Restriction Time: Adaptive Restricted Mean Survival Time Methods in Clinical Trials
· Biometrika · 2026-09-22 · 在第 6 页
Comparing Missing Data Strategies for Generalized Pairwise Comparisons in Randomized Clinical Trials: A Simulation Study
· SiM · 2026-09-17 · 在第 6 页
Seamless dose optimization design accounting for unknown patient heterogeneity in cancer clinical trials
· Biometrics · 2026-09-16 · 在第 6 页
Event‐Driven Type Design for Clinical Trials With Recurrent Events
· SiM · 2026-09-14 · 在第 6 页
Adaptive design strategies for ethical and efficient clinical trials using simulated annealing
· SMMR · 2026-09-14 · 在第 6 页
Sample size calculation for the sequential multiple assignment randomized trial (SMART) design with a skewed outcome: Application to the SMART+ study
· SMMR · 2026-09-12 · 在第 6 页
The Efficient Deployment of Police Resources: Theory and New Evidence from a Randomized Drunk Driving Crackdown in India
· Econometrica · 2026-09-10 · 在第 7 页
Covariate-adaptive randomization with dropouts
· SMMR · 2026-09-10 · 在第 7 页
Bayesian optimization for identification of optimal biological dose combinations in personalized dose-finding trials
· Biometrics · 2026-09-10 · 在第 7 页
A Bayesian model averaging method for dose ranging studies in oncology
· Biometrics · 2026-09-09 · 在第 7 页
Sample size determination for a prospective bridging study to harmonize retrospective data from multiple studies—Application to a biofluid biomarker study of Alzheimer’s disease
· SMMR · 2026-09-08 · 在第 7 页
Adaptive Trial Designs for Assessing Predictiveness of a Biomarker in Early Phase Drug Development
· SiM · 2026-09-08 · 在第 8 页
A Bayesian phase I/II trial design to optimizing dose–schedule regimen with competing risk outcomes
· SMMR · 2026-09-08 · 在第 8 页
Robust Bayesian hierarchical models for basket trials enabling joint evaluation of toxicity and efficacy
· SMMR · 2026-09-02 · 在第 8 页
Finite‐Sample Adjustments in Estimating Equations for Correlated Overdispersed Count Outcomes With Application to Cluster Randomized Trials
· SiM · 2026-08-31 · 在第 8 页
Group Sequential Design with Posterior and Posterior Predictive Probabilities
· JASA · 2026-08-27 · 在第 8 页
Anytime-Valid Inference in Linear Models with Applications to Regression-Adjusted Causal Inference
· JASA · 2026-08-27 · 在第 9 页
Family‐Wise Error Rate Control in Clinical Trials With Overlapping Populations
· SiM · 2026-08-25 · 在第 9 页
Inclusive designs that allow the inclusion of a broader population in randomized controlled trials: An evaluation of randomization ratio and analysis strategy
· SMMR · 2026-08-21 · 在第 9 页
Blinded sample size recalculation in randomized controlled trials with analysis of covariance
· Biometrics · 2026-08-20 · 在第 9 页
Long Run Non‐Transitivity of Win Ratio and How to Rule It Out
· SiM · 2026-08-19 · 在第 9 页
What is estimated in cluster randomized crossover trials with informative sizes? A survey of estimands and common estimators
· SMMR · 2026-08-08 · 在第 10 页
Bayesian Estimation of the Binomial Parameter in Adaptive Designs With Treatment Selection
· SiM · 2026-08-07 · 在第 10 页
Stratification in small randomised clinical trials and analysis of covariance: Some simple theory and recommendations
· SMMR · 2026-08-05 · 在第 10 页
Conditional Estimations for Seamless Phase II / III Clinical Trials Involving Multi‐Stage Early Stopping
· SiM · 2026-08-04 · 在第 11 页
BAP: Bayesian Biomarker-Assisted Platform Design for Dose Ranging in Multi-Agent Multi-Dose Trials
· JASA · 2026-08-03 · 在第 11 页
Sample Size and Power Calculations for Causal Inference in Observational Studies
· AoS · 2026-08-01 · 在第 11 页
A Bayesian Optimal Adaptive Clinical Trial Design for Sequentially Integrated Therapies
· SiM · 2026-07-30 · 在第 11 页
Pragmatic Two‐Stage Design for Clinical Trials With Treatment Selection
· SiM · 2026-07-27 · 在第 12 页
Statistical Methods in Medical Research- Volume: 35, Number: 7 (July 2026)
· SMMR · 2026-07-24 · 在第 12 页
Statistical Methods in Medical Research
· SMMR · 2026-07-24 · 在第 12 页
Improving survey inference in two-phase designs using Bayesian machine learning
· JRSSA · 2026-07-24 · 在第 13 页
Group sequential clinical trial designs for composite endpoints incorporating recurrent and terminal events
· Biometrics · 2026-07-24 · 在第 13 页
COADVISE: covariate adjustment with variable selection in randomized controlled trials
· JRSSA · 2026-07-24 · 在第 14 页
Designing Efficient Multicenter Trials With a Maximin Strategy
· SiM · 2026-07-21 · 在第 14 页
Clinical Trial Modernization: Technological, Operational, and Regulatory Advances
· JASA · 2026-07-20 · 在第 14 页
Efficiency Enhancement in Testing Treatment Efficacy Across Multiple Populations Using Treatment Crossover Data
· SiM · 2026-07-15 · 在第 14 页
Frequentist Identification of Effective Baskets via the Generalized Information Criteria in Oncology Phase 2 Trials
· SiM · 2026-07-14 · 在第 15 页
Bias reduction in g-computation for covariate adjustment in randomized clinical trials
· Biometrics · 2026-07-13 · 在第 15 页
Modeling treatment effects on absorbing outcomes in clinical trials: Leveraging longitudinal and ordinal data for efficiency gains
· SMMR · 2026-07-07 · 在第 15 页
Interim analysis in sequential multiple assignment randomized trials for survival outcomes
· Biometrics · 2026-07-07 · 在第 15 页
A Cautionary Note for Plasmode Simulation Studies in the Setting of Causal Inference
· SiM · 2026-07-07 · 在第 15 页
Interpretable Bayesian Modeling for Multireader Multicase Studies: Addressing Overdispersion and Limited Sample Size in Diagnostic Enhancement Evaluation
· SiM · 2026-07-03 · 在第 15 页
Asymptotic online FWER control for dependent test statistics
· SMMR · 2026-07-02 · 在第 16 页
A Multi‐Stage Drop‐the‐Loser Design With Superiority Boundaries
· SiM · 2026-06-24 · 在第 17 页
A Bayesian phase I/II platform design with data augmentation accounting for delayed outcomes
· Biometrics · 2026-06-19 · 在第 18 页
A generalized difference-in-differences estimator for stepped-wedge cluster-randomized trials
· Biometrics · 2026-06-16 · 在第 18 页
A Causal Framework for Evaluating the Total Effect of Strategies Aiming to Expand Screening and to Improve Outcomes
· SiM · 2026-06-15 · 在第 18 页
Design and Analysis of Randomized Clinical Trials With Average Hazard: Practical Guidance and Tools for Implementation
· SiM · 2026-06-14 · 在第 18 页
Two-phase treatment with noncompliance: identifying the cumulative average treatment effect via multisite instrumental variables
· JRSSA · 2026-06-12 · 在第 18 页
Improving Variance and Confidence Interval Estimation in Small‐Sample Propensity Score Analyses: Bootstrap Versus Asymptotic Methods
· SiM · 2026-06-11 · 在第 18 页
Selective randomization inference for adaptive experiments
· JRSSB · 2026-06-08 · 在第 19 页
Empirical Comparison of Win Ratio and Joint Frailty Models for Recurrent Event Endpoints With Applications in Oncology and Cardiology
· SiM · 2026-06-07 · 在第 19 页
Minimum noninferiority dose for phase I clinical trials with immunotherapy
· Biometrics · 2026-06-04 · 在第 19 页
Leveraging External Data in Rare Disease Trials Through Individualized Discounting Within the Power Prior: A Case Study in Hereditary Angioedema
· JASA · 2026-06-04 · 在第 19 页
Integrative learning of individualized treatment rules from multiple studies with partially overlapping treatments
· Biometrics · 2026-06-02 · 在第 20 页
Statistical inference in tensor completion: Optimal uncertainty quantification and statistical-to-computational gaps
· AoS · 2026-06-01 · 在第 20 页
Improving Sensitivity Analysis By Synthesizing Randomized Clinical Trials With Limited Overlap
· SiM · 2026-06-01 · 在第 20 页
Bayesian adaptive design for clinical trials with potential subgroup effects
· SMMR · 2026-06-01 · 在第 20 页
An evaluation of designs for Phase I/IIa dose-finding studies in Tuberculosis
· SMMR · 2026-06-01 · 在第 20 页
Sample Size Determination for Response‐Adaptive Randomization With Recurrent Event Responses and Unequal Follow‐Up Time
· SiM · 2026-05-31 · 在第 20 页
TITE-safety: a robust time-to-event safety monitoring approach for clinical trials
· Biometrics · 2026-05-27 · 在第 21 页
Principal stratification with U-statistics under principal ignorability
· JRSSB · 2026-05-27 · 在第 21 页
Computationally Efficient Approach to Operational Prior Specification in Phase I Clinical Trials
· SiM · 2026-05-27 · 在第 21 页
Safety‐Driven Response Adaptive Randomization: An Application in Noninferiority Oncology Trials
· SiM · 2026-05-26 · 在第 21 页
Sample Size Calculation for the ROCI Design
· SiM · 2026-05-25 · 在第 21 页
A Bayesian decision-theoretic approach to multiple testing in basket trials
· Biometrics · 2026-05-25 · 在第 21 页
Covariate-Adjusted Response-Adaptive Design with Delayed Outcomes
· JASA · 2026-05-21 · 在第 22 页
Power of the lack-of-fit test in designed experiments: Guidance on sample size and the distribution of replicates
· JASA · 2026-05-18 · 在第 22 页
On the Inclusion of Non‐Concurrent Controls in Platform Trials With an Interim Analysis
· SiM · 2026-05-18 · 在第 22 页
Exploring Sensitive Biomarkers Associated With Short‐Term Responses and Long‐Term Outcomes Using Bayesian Additive Regression Trees
· SiM · 2026-05-18 · 在第 22 页
Two‐Stage Double‐Arm Trial Optimal Design of Restricted Mean Survival Time With Sculpted Critical Region
· SiM · 2026-05-17 · 在第 22 页
Efficient interaction analysis in randomized controlled trials
· Biometrics · 2026-05-14 · 在第 23 页
A Bayesian phase I/II platform design with survival efficacy endpoint for dose optimization
· SMMR · 2026-05-14 · 在第 23 页
Synergy Area With FDR ‐Controlled Evaluation ( SAFE ) to Robustly Assess Safety Profile in Clinical Trials
· SiM · 2026-05-08 · 在第 23 页
Model‐Assisted Bayesian Estimators of Transparent Population Level Summary Measures for Ordinal Outcomes in Randomized Controlled Trials
· SiM · 2026-05-08 · 在第 23 页
Innovative Clinical Trial Approach for Evaluating Digital Medical Devices Under European Fast‐Track Regulatory Frameworks
· SiM · 2026-05-05 · 在第 23 页
Doubly Robust Estimators of the Restricted Mean Time in Favor Estimands in Individual‐ and Cluster‐Randomized Trials
· SiM · 2026-05-05 · 在第 23 页
Sample Size Determination for Comparing Slopes in Cluster Randomized Trials With Longitudinal Measurements
· SiM · 2026-05-04 · 在第 24 页
Dynamic Borrowing From Historical Controls via the Synthetic Prior With Covariates in Randomized Clinical Trials
· SiM · 2026-05-04 · 在第 24 页
Defining Utility as a Measure of Preference Under Uncertainty in Phase I– II Oncology Dose Finding Trials
· SiM · 2026-04-30 · 在第 24 页
Adaptive Designs in Trials With Time‐to‐Event Endpoints and Covariate Adjustment
· SiM · 2026-04-30 · 在第 24 页
When randomization is not random: Allocation bias in small sample, group sequential randomized clinical trials
· SMMR · 2026-04-29 · 在第 24 页
PRO-ADD: Patient-empowered dose-finding trials integrating safety, preliminary efficacy and patient-reported outcomes for optimal dose selection
· SMMR · 2026-04-29 · 在第 24 页
An Online Meta-Level Adaptive Design Framework with Targeted Learning Inference: Applications to Evaluating and Utilizing Surrogate Outcomes in Adaptive Designs
· JASA · 2026-04-28 · 在第 24 页
A Unified Framework for Statistical Inference and Power Analysis of Single and Comparative Fβ Scores
· SiM · 2026-04-28 · 在第 24 页
A Novel Group Sequential Design for Sequential Multiple Assignment Randomized Trial
· SiM · 2026-04-24 · 在第 25 页
Bayesian sample size determination using robust commensurate priors with interpretable discrepancy weights
· SMMR · 2026-04-16 · 在第 25 页
A practical review of response-adaptive randomization: Under-explored challenges and potential directions
· SMMR · 2026-04-16 · 在第 25 页
Expected Value of Sample Information Calculations for Risk Prediction Model Development
· SiM · 2026-04-13 · 在第 26 页
A Bayesian likely responder approach for the analysis of randomized controlled trials
· SMMR · 2026-04-08 · 在第 26 页
Vaccine efficacy estimands and power considerations
· SMMR · 2026-04-02 · 在第 26 页
Precise asymptotics of bagging regularized M-estimators
· AoS · 2026-04-01 · 在第 27 页
Making all pairwise comparisons in multi-arm clinical trials without control treatment
· Biometrics · 2026-03-27 · 在第 28 页
Asymptotic validity of Schoenfeld’s sample size formula for the Cox proportional hazards model via the Wald test approach
· SMMR · 2026-03-23 · 在第 28 页
Nonparametric ANCOVA for longitudinal outcomes in a randomized clinical trial
· Biometrics · 2026-03-20 · 在第 29 页
Analysis of Stepped‐Wedge Cluster Randomized Trials: A Tutorial Using Marginal Models
· SiM · 2026-03-20 · 在第 29 页
Covariate Adjustment in Basket Trials Borrowing Information Across Subgroups
· SiM · 2026-03-19 · 在第 29 页
What Makes an Estimand Useful? Guidance on the Choice of Intercurrent Event Strategies
· SiM · 2026-03-18 · 在第 29 页
Sample Size Recalculation in Adaptive Group Sequential Study Designs for Comparing Restricted Mean Survival Times
· SiM · 2026-03-18 · 在第 29 页
SIMBA–a Bayesian decision framework for the identification of optimal biomarker subgroups for cancer basket clinical trials
· Biometrics · 2026-03-18 · 在第 29 页
Clinical Trial Simulation: Planning With the OCTAVE Framework, Implementation and Validation Principles
· SiM · 2026-03-16 · 在第 29 页
A Note on “A Comparison of Two Methods for Adaptive Multi‐Arm Two‐Stage Design”
· SiM · 2026-03-16 · 在第 30 页
Efficient design of partially nested randomized trials: A maximin approach
· SMMR · 2026-03-13 · 在第 30 页
Location‐Scale Latent Process Model for Repeated Ordinal Patient‐Reported Outcomes
· SiM · 2026-03-12 · 在第 30 页
Dynamic Borrowing With a Bias‐Tolerance Cap in Augmented Randomized Controlled Trials
· SiM · 2026-03-12 · 在第 30 页
Design of Bayesian Clinical Trials With Clustered Data
· SiM · 2026-03-12 · 在第 30 页
Comparing HIV Vaccine Immunogenicity Across Trials With Different Populations and Study Designs
· SiM · 2026-03-09 · 在第 30 页
Bayesian Ordered Lattice Design for Phase I Clinical Trials
· SiM · 2026-03-04 · 在第 30 页
Inverse Probability Weighting for Recurrent Event Models
· SiM · 2026-02-27 · 在第 31 页
Applying the Partial Order Continual Reassessment Method to High‐Dimensional Treatment Combinations
· SiM · 2026-02-27 · 在第 31 页
Sample Sizes for Clinical Trials (second edition)
· Biometrics · 2026-02-23 · 在第 31 页
Confidence intervals and point estimates for treatment effects in adaptive enrichment designs
· SMMR · 2026-02-23 · 在第 31 页
An Introduction to Clinical Trials
· Biometrics · 2026-02-23 · 在第 31 页
Parameterizing the effect of a continuous treatment using average derivative effects
· Biometrika · 2026-02-19 · 在第 31 页
Dirichlet Distribution Parameter Estimation With Applications in Microbiome Analyses
· SiM · 2026-02-19 · 在第 31 页
A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials
· SiM · 2026-02-17 · 在第 32 页
Designing clinical trials for the comparison of single and multiple quantiles with right-censored data
· SMMR · 2026-02-16 · 在第 32 页
Patient‐Centric Pragmatic Clinical Trials: Opening the DOOR
· SiM · 2026-02-12 · 在第 32 页
Repeated inclusion cluster randomized trials: a new class of designs for assessing group-level interventions
· Biometrics · 2026-02-11 · 在第 32 页
Rank-based methods for assessing equivalence/non-inferiority with assay sensitivity in a three-arm trial with ordinal endpoints
· SMMR · 2026-02-11 · 在第 32 页
Doubly balanced samples with dynamic sample sizes
· Biometrics · 2026-02-11 · 在第 32 页
Bayesian Sample Size Calculations for External Validation Studies of Risk Prediction Models
· SiM · 2026-02-11 · 在第 32 页
A framework for causal estimand selection under positivity violations
· Biometrics · 2026-02-11 · 在第 32 页
Sample Size Re‐Estimation in Blinded Hybrid‐Control Design Using Inverse Probability Weighting
· SiM · 2026-02-10 · 在第 32 页
Probability of Success for Establishing Noninferiority Across Multiple Visits: Extension of Covariate‐Adjusted Bayesian Hierarchical Modeling Framework
· SiM · 2026-02-10 · 在第 32 页
On Anticipation Effect in Stepped Wedge Cluster Randomized Trials
· SiM · 2026-02-10 · 在第 32 页
Exact Randomized Two‐Stage Phase 2 Clinical Trial Designs for Two Binary Co‐Primary Endpoints
· SiM · 2026-02-10 · 在第 32 页
Estimands and Doubly Robust Estimation for Cluster-Randomized Trials With Survival Outcomes
· SiM · 2026-02-09 · 在第 33 页
A Bayesian Approach to Estimate Causal Average Treatment Effects Under Unmeasured Confounding
· SiM · 2026-02-09 · 在第 33 页
A hybrid prior Bayesian method for combining domestic real-world data and overseas data in global drug development
· SMMR · 2026-02-06 · 在第 33 页
A Causal Perspective on "Appropriate Implementation of ICH E9(R1) Addendum Strategies" (Comment on Fleming et al.)
· SiM · 2026-02-06 · 在第 33 页
Preference‐Informed Cluster Randomized Design for Pragmatic Clinical Trials
· SiM · 2026-02-05 · 在第 33 页
Patient Retreat in Dose Escalation for Phase I Clinical Trials With Rare Diseases
· SiM · 2026-02-05 · 在第 33 页
An Empirical Assessment of the Cost of Dichotomization of the Outcome of Clinical Trials
· SiM · 2026-02-05 · 在第 33 页
Adaptive Seamless Phase II/III Randomization Test Considering Treatment Group Selection Based on Short-Term Binary Outcomes
· SiM · 2026-02-04 · 在第 33 页
Bayesian randomized basket trial design: a case study from the ultra-rare invasive mold infections
· Biometrics · 2026-01-29 · 在第 34 页
A historical note: Rediscovering an unpublished response to Korn and Freidlin (2011)
· SMMR · 2026-01-28 · 在第 34 页
Modern Causal Inference Approaches to Improve Power for Subgroup Analysis in Randomized Controlled Trials
· SiM · 2026-01-27 · 在第 34 页
Sequential Event Rate Monitoring
· SiM · 2026-01-22 · 在第 35 页
Informative Futility Rules Based on Conditional Assurance
· SiM · 2026-01-22 · 在第 35 页
Bayesian Response‐Adaptive Randomization for Cluster Randomized Controlled Trials
· SiM · 2026-01-22 · 在第 35 页
Bayesian Power Prior in Platform Trials With Non‐Concurrent Control for Binary Outcomes: Development and Comparative Evaluation
· SiM · 2026-01-22 · 在第 35 页
Analytical Evaluation of the 2‐in‐1 Adaptive Design for Binary Endpoints
· SiM · 2026-01-22 · 在第 35 页
An Improved Bayesian Pick-the-Winner (IBPW) Design for Randomized Phase II Clinical Trials
· SiM · 2026-01-22 · 在第 35 页
A Saddlepoint Framework for Accurate Inference in Multicenter Clinical Trials With Imbalanced Clusters
· SiM · 2026-01-22 · 在第 35 页
A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials
· SiM · 2026-01-22 · 在第 35 页
A Bayesian Multilevel Joint Modeling of Longitudinal and Survival Outcomes in Cluster Randomized Controlled Trial Studies
· SiM · 2026-01-22 · 在第 35 页
Generalized pairwise comparisons using pseudo-observations for time-to-event censored data in a randomized controlled trial setting
· SMMR · 2026-01-19 · 在第 35 页
Restricted mean survival time in cluster randomized trials with a small number of clusters: Improving variance estimation of the intervention effect from the pseudo-values regression
· SMMR · 2026-01-12 · 在第 36 页
Learning optimal early decision treatment rules with multi-domain intermediate outcomes
· Biometrics · 2026-01-08 · 在第 36 页
Jointly modeling multiple endpoints for efficient treatment effect estimation in randomized controlled trials
· Biometrics · 2026-01-08 · 在第 36 页
An adaptive design for optimizing treatment assignment in randomized clinical trials
· Biometrics · 2026-01-08 · 在第 36 页
Semiparametric piecewise accelerated failure time model for the analysis of immune-oncology clinical trials
· Biometrics · 2026-01-06 · 在第 36 页
Incorporating external data for analyzing randomized clinical trials: A transfer learning approach
· JMLR · 2026 · 在第 41 页
A Randomized Basket Trial Design for Dose Optimization Based on Bayesian Model Averaging Using Spike-and-Slab Priors
· SiM · 2026 · 在第 44 页